| DB ID | MyCo_3069 |
| Title | Contribution of (1,3)-beta-D-glucan to diagnosis of invasive candidiasis after liver transplantation |
| Year | 2015 |
| PMID | 25520448 |
| Fungal Diseases involved | Invasive candidiasis |
| Associated Medical Condition | Liver Transplantation |
| Genus | Candida |
| Species | parapsilosis |
| Organism | Candida parapsilosis |
| Ethical Statement | The institutional review board of Henri Mondor Hospital, France approved the study, and the database was declared to the French Data Protection Authority (Commission Nationale Informatique et Liberté; record 1199340). |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | France |
| Cohort | All consecutive patients who underwent liver transplantation at Henri Mondor Hospital in France between January and June 2013 were enrolled prospectively in the study. They were monitored weekly for colonization by Candida, and colonization index values were calculated. Serum samples were tested for BG (Fungitell; Cape Cod Inc.) at least weekly between liver transplantation and discharge from the hospital. A total of 52 patients (including 39 male patients) were enrolled, with a median age of 55 years (range, 31 to 69 years). |
| Cohort No. | 52 |
| Age Group | 31-69 |
| P Value | None |
| Sensitivity | 0.83 |
| Specificity | 0.89 |
| Positive Predictive Value | 0.5 |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Liver transplant recipients are at relatively high risk of developing invasive fungal disease (IFD). The most common invasive fungal pathogens are Candida spp., followed by Aspergillus spp.. Such infections develop in 5% to 10% of transplant recipients and are a major cause of postoperative morbidity and death. This is related in part to delayed or missed diagnoses because of the low sensitivity and specificity of the diagnostic tests currently available. |
| Technique | ELISA |
| Analysis Method | FDA approved Fungitell assay |
| ELISA kits | None |
| Assay Data | FDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA |
| Validation Techniques used | FDA approved Fungitell assay |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
